Reports

As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.

Global Antisense and RNAi Therapeutics Market: By Technology: RNA Interference, siRNA, miRNA, Antisense RNA; By Application: Oncology, Cardiovascular Diseases, Others; By Route of Administration; Regional Analysis; Historical Market and Forecast (2016-2026); Market Dynamics; Competitive Landscape; Industry Events and Developments

Global Antisense and RNAi Therapeutics Market Outlook

The global antisense and RNAi therapeutics market attained a value of USD 1.45 billion in 2020 and is expected to grow at a CAGR of 8.5% during the forecast period of 2021-2026 owing to companies that are developing molecules based on antisense technology.

 

Global Antisense and RNAi Therapeutics Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Properties and Applications

Antisense and RNAi therapeutics make particular and highly effective gene silencing possible. Antisense technology offers a chance to manipulate the expression of gene and thus, it is regarded as an efficient therapy for targeting ribonucleic acids (RNA). It is widely used for oncology, cardiovascular diseases, respiratory disorders, renal diseases, neurodegenerative disorders, genetic disorders, infectious diseases, and others.

 

Global Antisense and RNAi Therapeutics Market Vehicle Type

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Antisense and RNAi therapeutics industry can be further divided based on:

  • Technology
    • RNA interference
    • SiRNA
    • MiRNA
    • Antisense RNA 
  • Route of Administration
    • Pulmonary Delivery
    • Intravenous Injections
    • Intra-dermal Injections
    • Intraperitoneal Injections
    • Topical Delivery

The EMR report looks into the regional antisense and RNAi therapeutics markets like the North America, Latin America, Europe, Middle East and Africa, and Asia Pacific.

 

Global Antisense and RNAi Therapeutics Market by Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Analysis

The global antisense and RNAi therapeutics industry is being driven by intensive study of gene functioning for disease management, through the use of malfunctioning gene and controlling its gene expression. The market is further driven by various collaborations taking place between pharmaceutical companies and contract research organisations, working to enhance drug delivery.

 

Competitive Landscape

The report presents a detailed analysis of the following key players in the global antisense and RNAi therapeutics industry, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • OliX Pharmaceuticals Inc.
  • Sanofi S.A, SAN (EPA)
  • GlaxoSmithKline, GSK (LON)
  • Ionis Pharmaceuticals 
  • Benitec Biopharma Ltd 
  • Silence Therapeutics Plc 
  • Enzon Pharmaceuticals Inc 
  • Antisense Therapeutics Ltd.

The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s five forces.

 

REPORT FEATURES DETAILS
Base Year 2020
Historical Period 2016-2020
Forecast Period 2021-2026
Scope of the Report Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Technology, Application, Route of Administration, Region
Breakup by Technology RNA Interference, siRNA, miRNA, Antisense RNA
Breakup by Application Oncology, Cardiovascular Diseases, Respiratory Disorders, Renal Diseases, Neurodegenerative Disorders, Genetic Disorders, Infectious Diseases, Others
Breakup by Route of Administration Pulmonary Delivery, Intravenous Injections, Intra-dermal Injections, Intraperitoneal Injections, Topical Delivery, Others
Breakup by Region North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Market Dynamics SWOT, Porter's Five Forces, EMR’s Key Indicators for Price and Demand
Competitive Landscape Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications
Companies Covered OliX Pharmaceuticals Inc., Sanofi S.A, SAN (EPA), GlaxoSmithKline, GSK (LON), Ionis Pharmaceuticals, Benitec Biopharma Ltd, Silence Therapeutics Plc, Enzon Pharmaceuticals Inc, Antisense Therapeutics Ltd.
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key findings of the Study
2    Research Methodology
    2.1    Data Extraction
    2.2    Data Corroboration
    2.3    Market Structure
    2.4    Inference Data
3    Executive Summary
    3.1    Market Overview
    3.2    Market Analysis 
4    Global Antisense and RNAi Therapeutics Market 
    4.1    Global Antisense and RNAi Therapeutics Market (2016-2020) & Forecast (2021-2026)
    4.2    Global Antisense and RNAi Therapeutics Market Breakup by Technology 
        4.2.1    RNA Interference
        4.2.2    siRNA
        4.2.3    miRNA
        4.2.4    Antisense RNA
    4.3    Global Antisense and RNAi Therapeutics Market Breakup by Technology: Historical Market (2016-2020) & Forecast (2021-2026)
        4.3.1    RNA Interference
        4.3.2    siRNA
        4.3.3    miRNA
        4.3.4    Antisense RNA
    4.4    Global Antisense and RNAi Therapeutics Market Breakup by Application
        4.4.1    Oncology 
        4.4.2    Cardiovascular Diseases
        4.4.3    Respiratory Disorders
        4.4.4    Renal Diseases
        4.4.5    Neurodegenerative Disorders 
        4.4.6    Genetic Disorders 
        4.4.7    Infectious Diseases 
        4.4.8    Others
    4.5    Global Antisense and RNAi Therapeutics Market Breakup by Application: Historical Market (2016-2020) & Forecast (2021-2026)
        4.5.1    Oncology 
        4.5.2    Cardiovascular Diseases
        4.5.3    Respiratory Disorders
        4.5.4    Renal Diseases
        4.5.5    Neurodegenerative Disorders 
        4.5.6    Genetic Disorders 
        4.5.7    Infectious Diseases 
        4.5.8    Others
    4.6    Global Antisense and RNAi Therapeutics Market Breakup by Route of Administration
        4.6.1    Pulmonary Delivery 
        4.6.2    Intravenous Injections
        4.6.3    Intra-dermal Injections
        4.6.4    Intraperitoneal Injections 
        4.6.5    Topical Delivery
        4.6.6    Others 
    4.7    Global Antisense and RNAi Therapeutics Market Breakup by Route of Administration: Historical Market (2016-2020) & Forecast (2021-2026)
        4.7.1    Pulmonary Delivery 
        4.7.2    Intravenous Injections
        4.7.3    Intra-dermal Injections
        4.7.4    Intraperitoneal Injections 
        4.7.5    Topical Delivery
        4.7.6    Others 
    4.8     Global Antisense and RNAi Therapeutics Market Breakup by Region
        4.8.1    North America
            4.8.1.1    United States of America
            4.8.1.2    Canada
        4.8.2    Europe
            4.8.2.1    Germany
            4.8.2.2    United Kingdom
            4.8.2.3    France
            4.8.2.4    Italy
            4.8.2.5    Others
        4.8.3    Asia Pacific
            4.8.3.1    China
            4.8.3.2    Japan
            4.8.3.3    India
            4.8.3.4    ASEAN
            4.8.3.5    Others
        4.8.4    Latin America
            4.8.4.1    Brazil
            4.8.4.2    Argentina
            4.8.4.3    Mexico
            4.8.4.4    Others
        4.8.5    Middle East & Africa
            4.8.5.1    Saudi Arabia
            4.8.5.2    United Arab Emirates
            4.8.5.3    Nigeria
            4.8.5.4    South Africa
            4.8.5.5    Others
    4.9     Global Antisense and RNAi Therapeutics Market Breakup by Region: Historical Market (2016-2020) & Forecast (2021-2026)
        4.9.1    North America
            4.9.1.1    United States of America
            4.9.1.2    Canada
        4.9.2    Europe
            4.9.2.1    Germany
            4.9.2.2    United Kingdom
            4.9.2.3    France
            4.9.2.4    Italy
            4.9.2.5    Others
        4.9.3    Asia Pacific
            4.9.3.1    China
            4.9.3.2    Japan
            4.9.3.3    India
            4.9.3.4    ASEAN
            4.9.3.5    Others
        4.9.4    Latin America
            4.9.4.1    Brazil
            4.9.4.2    Argentina
            4.9.4.3    Mexico
            4.9.4.4    Others
        4.9.5    Middle East & Africa
            4.9.5.1    Saudi Arabia
            4.9.5.2    United Arab Emirates
            4.9.5.3    Nigeria
            4.9.5.4    South Africa
            4.9.5.5    Others
5    SWOT Analysis
    5.1    Overview
    5.2    Strengths
    5.3    Weaknesses
    5.4    Opportunities
    5.5    Threats
6    Porter’s Five Forces Analysis
    6.1    Overview
    6.2    Buyer’s Power
    6.3    Supplier’s Power
    6.4    New Entrants
    6.5    Degree of Rivalry
    6.6    Substitutes
7    Key Players & Company Profile Analysis 
    7.1    OliX Pharmaceuticals Inc.
    7.2    Sanofi S.A, SAN (EPA)
    7.3    GlaxoSmithKline, GSK (LON)
    7.4    Ionis Pharmaceuticals 
    7.5    Benitec Biopharma Ltd 
    7.6    Silence Therapeutics Plc 
    7.7    Enzon Pharmaceuticals Inc 
    7.8    Antisense Therapeutics Ltd.
8    Industry Events and Developments

Key Questions Answered in the Report

In 2020, the global antisense and RNAi therapeutics market attained a value of nearly USD 1.45 billion.

The market is projected to grow at a CAGR of 8.5% between 2021 and 2026.

The major industry drivers are intensive study of gene functioning for disease management, through the use of malfunctioning gene, and controlling its gene expression.

The key trends in the market are various collaborations taking place between pharmaceutical companies and contract research organisations, working to enhance drug delivery.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

The technology types include RNA interference, siRNA, miRNA, and antisense RNA.

The application sectors include oncology, cardiovascular diseases, respiratory disorders, renal diseases, neurodegenerative disorders, genetic disorders, and infectious diseases, among others.

The routes of administration include pulmonary delivery, intravenous injections, intra-dermal injections, intraperitoneal injections, and topical delivery, among others.

The major players in the industry are OliX Pharmaceuticals Inc., Sanofi S.A, SAN (EPA), GlaxoSmithKline, GSK (LON), Ionis Pharmaceutical, Benitec Biopharma Ltd, Silence Therapeutics Plc, Enzon Pharmaceuticals Inc., and Antisense Therapeutics Ltd.

Analyst Review

The global antisense and RNAi therapeutics market attained a value of USD 1.45 billion in 2020, driven by the intensive study of gene functioning for disease management, through the use of malfunctioning gene and controlling its gene expression. Aided by the various collaborations taking place between pharmaceutical companies and contract research organisations, working to enhance drug delivery, the market is expected to witness a further growth in the forecast period of 2021-2026, growing at a CAGR of 8.5%.

EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. The technology types include RNA interference, siRNA, miRNA, and antisense RNA. The application sectors include oncology, cardiovascular diseases, respiratory disorders, renal diseases, neurodegenerative disorders, genetic disorders, and infectious diseases, among others. The routes of administration include pulmonary delivery, intravenous injections, intra-dermal injections, intraperitoneal injections, and topical delivery, among others. The major regional markets for antisense and RNAi therapeutics are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include OliX Pharmaceuticals Inc., Sanofi S.A, SAN (EPA), GlaxoSmithKline, GSK (LON), Ionis Pharmaceutical, Benitec Biopharma Ltd, Silence Therapeutics Plc, Enzon Pharmaceuticals Inc., and Antisense Therapeutics Ltd.

EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.

Purchase Full Report

Mini Report

$1499
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$2699
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

$3699
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$4699
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

RIGHT PEOPLE

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

RIGHT METHODOLOGY

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

RIGHT PRICE

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

RIGHT SUPPORT

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

Similar Reports





NEWSLETTER